---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005188"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:35:58.478855+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bio-Path reports FY2022 net loss of $13.9M ($1.91/share); cash drops to $10.4M

## Summary
- Net loss $13.9M ($1.91 per share) vs $10.4M ($1.55) in 2021; R&D expense rose to $9.2M.
- Cash at Dec 31, 2022 was $10.4M, down from $23.8M; operating cash burn of $15.1M.
- First patient dosed in Phase 1/1b trial of BP1001-A in solid tumors (ovarian, pancreatic, breast).
- Phase 2 prexigebersen AML trial: two cohorts exceeded minimum efficacy; interim analyses expected Q2 2023.
- BP1002 Phase 1/1b in relapsed/refractory AML: initial cohort data readout expected Q2 2023.

## SEC filing metadata
- accession: 0001558370-23-005188
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/0001558370-23-005188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/bpth-20230331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005188
- JSON: https://secwatch.observer/filing/0001558370-23-005188.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005188.txt

## Key facts
- Earnings Releases
  BIO-PATH HOLDINGS, INC. reported the year ended December 31, 2022 results: net income a net loss of $13.9 million, or $1.91 per share.
  - Period: the year ended December 31, 2022
  - Net income: a net loss of $13.9 million, or $1.91 per share
  - Result: reported results
  source text: The Company reported a net loss of $13.9 million, or $1.91 per share, for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133818/000155837023005188/0001558370-23-005188-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.